Using the same assay and scoring algorithm in the phase III DANUBE trial of previously untreated patients, those who had high tumor PD-L1 expression survived longer than the all-comer population when treated with durvalumab or durvalumab plus tremelimumab (32). Here, CD274 is linked to neoplasm.